OptiBiotix Health plc (AIM: OPTI), a life sciences company specialising in microbiome-based health products, announced on Wednesday that it has signed a distribution agreement with a well-known direct selling weight management company.
Under the deal, OptiBiotix will supply SlimBiome finished products under the distributor's branding, as well as a WellBiome product to be included in its portfolio. The distributor plans to launch first in its largest sales territory, followed by other European markets, with products available through both e-commerce and a long-established consultant network. An initial order is expected within three months, with the official launch anticipated in H1 2026.
The agreement highlights growing demand for functional ingredients that complement the surge of interest in anti-obesity drugs. OptiBiotix's products are positioned to add scientifically backed functionality to established weight management brands.
Founded in 2012, OptiBiotix develops microbiome modulators targeting obesity, cardiovascular health and diabetes. The company has signed over 20 agreements with international food and healthcare firms and continues to expand its consumer supplement portfolio.
GSK wins European Commission approval for Shingrix prefilled syringe
Tri-City Cardiology adds new members to care team
GENinCode expands Mexico presence with CARDIO inCode-Score distribution agreement
Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA
InsiteOne agrees strategic partnerships with ASCEND Cardiovascular and Apollo Enterprise Imaging
Gan & Lee Pharmaceuticals launches third phase 3 trial of once-monthly bofanglutide
Remington Medical's VascuChek 2.0 Cordless Bluetooth-Enabled Doppler Secures FDA Clearance
LivaNova secures higher Medicare reimbursement for VNS Therapy procedures